eMedicine Specialties > Ophthalmology > Retina

Retinopathy, Diabetic, Background

Abdhish R Bhavsar, MD, Adjunct Assistant Professor, Department of Ophthalmology, University of Minnesota Medical School; Director of Clinical Research, Retina Center, PA; Past Chair, Consulting Staff, Department of Ophthalmology, Phillips Eye Institute
John H Drouilhet, MD, FACS, Clinical Professor, Department of Surgery, Section of Ophthalmology, University of Hawaii, John A Burns School of Medicine

Updated: Oct 6, 2009

Introduction

Background

Diabetes mellitus (DM) is a major medical problem throughout the world. Diabetes causes an array of long-term systemic complications, which have considerable impact on both the patient and the society because it typically affects individuals in their most productive years.¹ Ophthalmic complications of diabetes include corneal abnormalities, glaucoma, iris neovascularization, cataracts, and neuropathies. However, the most common and potentially most blinding of these complications is diabetic retinopathy.^2,3

Pathophysiology

The exact mechanism by which diabetes causes retinopathy remains unclear, but several theories have been postulated to explain the typical course and history of the disease.^4,5

Growth hormone

Growth hormone appears to play a causative role in the development and progression of diabetic retinopathy. It was noted that diabetic retinopathy was reversed in women who had postpartum hemorrhagic necrosis of the pituitary gland (Sheehan syndrome). This led to the controversial practice of pituitary ablation to treat or prevent diabetic retinopathy in the 1950s. This technique has been abandoned because of numerous systemic complications and the discovery of the effectiveness of laser treatment.

Platelets and blood viscosity

The variety of hematologic abnormalities seen in diabetes, such as increased erythrocyte aggregation, decreased RBC deformability, increased platelet aggregation, and adhesion, predispose to sluggish circulation, endothelial damage, and focal capillary occlusion. This leads to retinal ischemia, which, in turn, contributes to the development of diabetic retinopathy.

Aldose reductase and vasoproliferative factors

Fundamentally, diabetes mellitus (DM) causes abnormal glucose metabolism as a result of decreased levels or activity of insulin. Increased levels of blood glucose are thought to have a structural and physiologic effect on retinal capillaries causing them to be both functionally and anatomically incompetent.

A persistent increase in blood glucose levels shunts excess glucose into the aldose reductase pathway in certain tissues, which converts sugars into alcohol (eg, glucose into sorbitol, galactose to dulcitol). Intramural pericytes of retinal capillaries seem to be affected by this increased level of sorbitol, eventually leading to the loss of its primary function (ie, autoregulation of retinal capillaries).

Loss of function of pericytes results in weakness and eventual saccular outpouching of capillary walls. These microaneurysms are the earliest detectable signs of DM retinopathy.

Fundus photograph of early background diabetic retinopathy showing multiple microaneurysms.

Retinal findings in background diabetic retinopathy, including blot hemorrhages (arrowhead), microaneurysms (short arrow), and hard exudates (long arrow).

Increased permeability of these vessels results in leakage of fluid and proteinaceous material, which clinically appears as retinal thickening and exudates. If the swelling and exudation would happen to involve the macula, a diminution in central vision may be experienced. Macular edema is the most common cause of vision loss in patients with nonproliferative diabetic retinopathy (NPDR). However, it is not exclusively seen only in patients with NPDR, but it also may complicate cases of proliferative diabetic retinopathy (PDR).

Another theory to explain the development of macular edema deals with the increased levels of diacylglycerol (DAG) from the shunting of excess glucose. This is thought to activate protein kinase C (PKC), which, in turn, affects retinal blood dynamics, especially permeability and flow, leading to fluid leakage and retinal thickening.

As the disease progresses, eventual closure of the retinal capillaries occurs, leading to hypoxia. Infarction of the nerve fiber layer leads to the formation of cotton-wool spots (CWS) with associated stasis in axoplasmic flow.

More extensive retinal hypoxia triggers compensatory mechanisms within the eye to provide enough oxygen to tissues. Venous caliber abnormalities, such as venous beading, loops, and dilation, signify increasing hypoxia and almost always are seen bordering the areas of capillary nonperfusion. Intraretinal microvascular abnormalities (IRMA) represent either new vessel growth or remodeling of preexisting vessels through endothelial cell proliferation within the retinal tissues to act as shunts through areas of nonperfusion.

Further increases in retinal ischemia trigger the production of vasoproliferative factors that stimulate new vessel formation. The extracellular matrix is broken down first by proteases, and new vessels arising mainly from the retinal venules penetrate the internal limiting membrane and form capillary networks between the inner surface of the retina and the posterior hyaloid face.

Neovascularization most commonly is observed at the borders of perfused and nonperfused retina and most commonly occur along the vascular arcades and at the optic nerve head. The new vessels break through and grow along the surface of the retina and into the scaffold of the posterior hyaloid face. By themselves, these vessels rarely cause visual compromise. However, they are fragile and highly permeable. These delicate vessels are disrupted easily by vitreous traction, which leads to hemorrhage into the vitreous cavity or the preretinal space.

These new blood vessels initially are associated with a small amount of fibroglial tissue formation. However, as the density of the neovascular frond increases, so does the degree of fibrous tissue formation. In later stages, the vessels may regress leaving only networks of avascular fibrous tissue adherent to both the retina and the posterior hyaloid face. As the vitreous contracts, it may exert tractional forces on the retina via these fibroglial connections. Traction may cause retinal edema, retinal heterotropia, and both tractional retinal detachments and retinal tear formation with subsequent detachment.

Frequency

United States

Approximately 16 million Americans have diabetes, with 50% of them not even aware that they have it. Of those that know, only one half receives appropriate eye care. Thus, it is not surprising that diabetic retinopathy is the leading cause of new blindness in persons aged 25-74 years in the United States, responsible for more than 8000 cases of new blindness each year.⁶ This means that diabetes is responsible for 12% of blindness; the rate is even higher among certain ethnic groups.

International

The incidence of diabetes appears to be increasing throughout the world, at least in part due to the increasing incidence of obesity and sedentary lifestyle. Dietary changes involving diets with higher fat and carbohydrate intake as well as the increasing size of portions of food and drinks over the past several decades may also be responsible.

Mortality/Morbidity

The treatment of diabetic retinopathy entails tremendous costs, but it has been estimated that this represents only one eighth of the costs of social security payments for vision loss. This cost does not compare to the cost in terms of loss of productivity and quality of life.

Race

An increased risk of diabetic retinopathy appears to exist in patients with Native American, Hispanic, and African American heritage.

Sex

Sex does not appear to have any affect on the development of diabetes or diabetic retinopathy.

Age

With increasing duration of diabetes, or with increasing age since the onset of diabetes, there is a higher risk of developing diabetic retinopathy and the complications of diabetic retinopathy, including diabetic macular edema or proliferative diabetic retinopathy.

Clinical

History

In the initial stages, patients are generally asymptomatic; however, in the more advanced stages of the disease, patients may experience symptoms, including blurred vision, distortion, or visual acuity loss.

Physical

• Microaneurysms
  • Earliest clinical sign of diabetic retinopathy
  • Secondary to capillary wall outpouching due to pericyte loss
  • Appear as small red dots in the superficial retinal layers
  • Fibrin and RBC accumulation in the microaneurysm lumen
  • Rupture produces blot/flame hemorrhages
  • May appear yellowish in time as endothelial cells proliferate and produce basement membrane
• Dot and blot hemorrhages
  • Occur as microaneurysms rupture in the deeper layers of the retina such as the inner nuclear and outer plexiform layers
  • Appear similar to microaneurysms if they are small; may need fluorescein angiography to distinguish between the two
• Flame-shaped hemorrhages - Splinter hemorrhages that occur in the more superficial nerve fiber layer
• Retinal edema and hard exudates - Caused by the breakdown of the blood-retina barrier, allowing leakage of serum proteins, lipids, and protein from the vessels
• Cotton-wool spots
  • Nerve fiber layer infarction from occlusion of precapillary arterioles
  • Fluorescein angiography - No capillary perfusion
  • Frequently bordered by microaneurysms and vascular hyperpermeability
• Venous loops, venous beading
  • Frequently adjacent to areas of nonperfusion
  • Reflects increasing retinal ischemia
  • Most significant predictor of progression to PDR
• Intraretinal microvascular abnormalities
  • Remodeled capillary beds without proliferative changes
  • Collateral vessels that do not leak on fluorescein angiography
  • Usually can be found on the borders of the nonperfused retina
• Macular edema
  • This condition is the leading cause of visual impairment in patients with diabetes. A reported 75,000 new cases of macular edema are diagnosed annually.
  • Possibly due to functional damage and necrosis of retinal capillaries
  • Clinically significant macular edema (CSME) is defined as any of the following:
    • Retinal thickening located 500 µm or less from the center of the foveal avascular zone (FAZ)
    • Hard exudates with retinal thickening 500 µm or less from the center of the FAZ
    • Retinal thickening 1 disc area or larger in size located within 1 disc diameter of the FAZ
• Mild nonproliferative diabetic retinopathy - Presence of at least 1 microaneurysm
• Moderate nonproliferative diabetic retinopathy
  • Presence of hemorrhages, microaneurysms, and hard exudates
  • Soft exudates, venous beading, and IRMA less than that of severe NPDR
• Severe nonproliferative diabetic retinopathy (4-2-1)
  • Hemorrhages and microaneurysms in 4 quadrants
  • Venous beading in at least 2 quadrants
  • IRMA in at least 1 quadrant
• Mild NPDR reflects structural changes in the retina caused by the physiological and anatomical effects of diabetes. On the other hand, the more advanced stages of NPDR reflect the increasing retinal ischemia setting up the stage for proliferative changes.

Causes

Risk factors

• Duration of the diabetes
  • In patients with type I diabetes, no clinically significant retinopathy can be seen in the first 5 years after the initial diagnosis of diabetes is made. After 10-15 years, 25-50% of patients show some signs of retinopathy. This prevalence increases to 75-95% after 15 years and approaches 100% after 30 years of diabetes.
  • In patients with type II diabetes, the incidence of diabetic retinopathy increases with the duration of the disease. Of patients with type II diabetes, 23% have NPDR after 11-13 years, 41% have NPDR after 14-16 years, and 60% have NPDR after 16 years.
• Glucose control
  • The Diabetic Control and Complications Trial (DCCT) has demonstrated that intensive glucose control reduced the incidence and the progression of diabetic retinopathy in patients with insulin-dependent diabetes mellitus (IDDM).
  • Although no similar trials for patients with non–insulin–dependent diabetes mellitus (NIDDM) have been completed, the American Diabetes Association (ADA) has suggested that glycosylated hemoglobin levels of less than 7% (reflecting long-term glucose levels) should be the goal in all patients to prevent or slow down the onset of diabetes-related complications.
• Renal disease, as evidenced by proteinuria and elevated BUN/creatinine levels, is an excellent predictor of the presence of retinopathy. This probably is due to the fact that both conditions are caused by DM-related microangiopathies such that the presence and severity of one reflects that of the other. Evidence suggests that aggressive treatment of the nephropathy may have a beneficial effect on the progression of diabetic retinopathy and neovascular glaucoma.
• Systemic hypertension, in the setting of diabetic nephropathy, correlates well with the presence of retinopathy. Independently, hypertension also may complicate diabetes in that it may result in hypertensive retinal vascular changes superimposed on the preexisting diabetic retinopathy, further compromising retinal blood flow.
• Proper management of hyperlipidemia (elevated serum lipids) may result in less retinal vessel leakage and hard exudate formation. The reason behind this is unclear.
• Pregnant women without any diabetic retinopathy run a 10% risk of developing NPDR during their pregnancy. Of those with preexisting NPDR, 4% progress to the proliferative type.

Differential Diagnoses

Branch Retinal Vein Occlusion
Central Retinal Vein Occlusion
Ocular Ischemic Syndrome
Retinopathy, Hemoglobinopathies
Sickle Cell Disease

Other Problems to Be Considered

Retinopathy, radiation

Workup

Laboratory Studies

• Fasting glucose and hemoglobin A1c (HbA1c) are important laboratory tests that are performed to help diagnose diabetes. The HbA1c level is also important in the long-term follow-up care of patients with diabetes and diabetic retinopathy. Controlling diabetes and maintaining the HbA1c level in the 6-7% range are the goals in the optimal management of diabetes and diabetic retinopathy. If the levels are maintained, then the progression of diabetic retinopathy is reduced substantially, according to the DCCT.

Imaging Studies

• Fluorescein angiography is an invaluable adjunct in the diagnosis and management of diabetic retinopathy.
  • Microaneurysms would appear as pinpoint hyperfluorescence that does not enlarge but rather fades in the later phases of the test.
  • Blot and dot hemorrhages can be distinguished from microaneurysms because they appear as hypofluorescent rather than hyperfluorescent.
  • Areas of nonperfusion appear as homogenous dark patches bordered by occluded blood vessels.
  • IRMA is evidenced by collateral vessels that do not leak, usually found in the borders of the nonperfused retina.

Other Tests

• Other tests may include optical coherence tomography (OCT), which uses light to generate a cross-sectional image of the retina. This is used to determine the thickness of the retina and the presence of swelling within the retina as well as vitreomacular traction. This test is particularly used for the diagnosis and management of diabetic macular edema or clinically significant macular edema.

Treatment

Medical Care

• Glucose control: The DCCT has found that intensive glucose control in patients with IDDM has decreased the incidence and progression of diabetic retinopathy.^7,8,9 Although no similar clinical trials for patients with NIDDM exist, it may be logical to assume that the same principles also apply. In fact, the ADA has suggested that all diabetics (NIDDM and IDDM) should strive to maintain glycosylated hemoglobin levels of less than 7% to prevent or at the very least to minimize the long-term complications of DM, including DM retinopathy.
• The Early Treatment for Diabetic Retinopathy Study (ETDRS) found that 650 mg of aspirin daily did not offer any benefit in preventing the progression of DM retinopathy. Additionally, aspirin was not observed to influence the incidence of vitreous hemorrhage in patients who required it for cardiovascular disease (CVD) or other conditions.^10,11

Surgical Care

The advent of laser photocoagulation in the 1960s and early 1970s provided a noninvasive treatment modality that has a relatively low complication rate and a significant degree of success. This involves directing a high-focused beam of light energy to create a coagulative response in the target tissue. In NPDR, laser treatment is indicated in the treatment of CSME. The strategy for treating macular edema depends on the type and extent of vessel leakage.

• If the edema is due to leakage of specific microaneurysms, the leaking vessels are treated directly with focal laser photocoagulation.¹²
• In cases where the foci of leakage are nonspecific, a grid pattern of laser burns is applied. Medium intensity burns (100-200 µm) are placed 1 burn size apart covering the affected area.
• Other off-label potential treatments of diabetic macular edema (DME) include intravitreal triamcinolone acetonide (Kenalog) and bevacizumab (Avastin). Both of these medications can result in a substantial reduction or resolution of macular edema.

Diet

A good healthy diet with well-balanced meals is important for all individuals and is particularly important for individuals with diabetes. A well-balanced diet can help to achieve better weight control and also better control of the diabetes. To that end, it can also help to reduce the complications of diabetes.

Activity

Maintaining a good healthy lifestyle with regular exercise is important for all individuals, especially for those individuals with diabetes. Exercise can help with maintaining weight and with peripheral glucose absorption. This can help with improved diabetes control, and this, in turn, can help to reduce the complication of diabetes and diabetic retinopathy.

Medication

Several medications are currently being used in an off-label manner in the treatment of diabetic retinopathy. At present, these medications are administered into the eye by intravitreal injection. Intravitreal triamcinolone is being used in the treatment of diabetic macular edema. A recent Diabetic Retinopathy Clinical Research Network (DRCR.net) clinical trial demonstrated that, although some reduction in macular edema occurred after intravitreal triamcinolone, this effect was not as robust as that achieved with focal laser treatment at the primary endpoint of 2 years.¹²  In addition, intravitreal triamcinolone can have some side effects, including steroid response with intraocular pressure increase and cataracts. 

Other medications that are being used in clinical practice and in clinical trials include intravitreal bevacizumab (Avastin) and ranibizumab (Lucentis). These medications are VEGF antibodies and antibody fragments, respectively. They can help to reduce diabetic macular edema and also neovascularization of the disc or retina. Combinations of some of these medications above with focal laser treatment are being investigated in the DRCR.net clinical trials.

Follow-up

Further Outpatient Care

• The frequency of follow-up care is dictated primarily on the baseline stage of the retinopathy and its rate of progression to proliferative diabetic retinopathy (PDR).
  • Only 5% of patients with mild NPDR would progress to PDR in 1 year and, thus, could be monitored every 6-12 months.
  • As many as 27% of patients with moderated NPDR would progress to PDR in 1 year; therefore, they should be seen every 4-8 months.
  • More than 50% of patients with severe NPDR (preproliferative stage) would progress to PDR in a year; thus, follow-up care as frequent as 2-4 months is mandated to ensure prompt recognition and treatment.
  • Any stage associated with clinically significant macular edema (CSME) should be treated and observed closely (every 2-3 mo) to monitor the status of the macula.

Deterrence/Prevention

• The Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UK-PDS) were large randomized clinical trials that demonstrated the importance of tight glucose control with respect to reducing the incidence and progression of diabetes complications including diabetic retinopathy for both type 1 and type 2 diabetes.¹³

Complications

• The complications of focal and grid laser therapy include the following:
  • Decreased central vision
  • Paracentral scotomas
  • Choroidal neovascularization
  • Epiretinal membrane formation
  • Further increase in macular edema

Prognosis

• The Early Treatment for Diabetic Retinopathy Study (ETDRS) has found that laser surgery for macular edema reduces the incidence of moderate visual loss (doubling of visual angle or roughly a 2-line visual loss) from 30% to 15% over a 3-year period.
• Favorable prognostic factors
  • Circinate exudates of recent onset
  • Well-defined leakage
  • Good perifoveal perfusion
• Unfavorable prognostic factors
  • Diffuse edema/multiple leaks
  • Lipid deposition in the fovea
  • Macular ischemia
  • Cystoid macular edema
  • Preoperative vision of less than 20/200
  • Hypertension

Patient Education

• One of the most important aspects in the management of diabetic retinopathy is patient education. Inform patients that they play an integral role in their own eye care. Emphasize the following facts:
  • Excellent glucose control is beneficial in any stage of diabetic retinopathy. It delays the onset and slows down the progression of the diabetic complications in the eye.
  • Other systemic problems, such as hypertension, renal disease, and hyperlipidemia, may contribute to the progression of the retinopathy and should be addressed promptly.
  • Smoking, although not directly proven to affect the course of the retinopathy, may play a role in further compromising oxygen delivery to the retina. Therefore, all efforts should be made in the reduction, if not outright cessation, of smoking.
  • Visual symptoms (eg, changes in vision, redness, pain) could be manifestations of disease progression and should be reported immediately.
  • DM in general and diabetic retinopathy in particular are progressive conditions such that regular follow-up care with a physician is crucial to detect any changes that may benefit from treatment.
• For excellent patient education resources, see eMedicine's Diabetes Center. Also, visit eMedicine's patient education article Diabetic Eye Disease.

Miscellaneous

Medicolegal Pitfalls

• Failure to emphasize to the patient that focal or grid laser treatment of clinically significant macular edema (CSME) is not aimed at improving vision but rather at reducing the risk of moderate visual loss.

Special Concerns

• All individuals with diabetes should be aware of the importance of regular dilated retinal examinations. Early diagnosis and treatment of diabetic retinopathy can help prevent blindness in more than 90% of cases. However, in spite of treatment, sometimes, individuals can still lose vision. The patient, ophthalmologist or retina specialist, and internist or endocrinologist must work together as a team to optimize the diabetes control and help to reduce the risk of blindness.

Multimedia

Media file 1: Fundus photograph of early background diabetic retinopathy showing multiple microaneurysms.

Media file 2: Retinal findings in background diabetic retinopathy, including blot hemorrhages (arrowhead), microaneurysms (short arrow), and hard exudates (long arrow).

Media file 3: Fluorescein angiogram demonstrating an area of capillary nonperfusion (arrow).

Media file 4: Fluorescein angiogram demonstrating foveal dye leakage caused by macular edema.

Media file 5: Fundus photograph of clinically significant macular edema demonstrating retinal exudates within the fovea.

References

1. Federman JL, Gouras P, Schubert H, et al. Systemic diseases. In: Podos SM, Yanoff M, eds. Retina and Vitreous: Textbook of Ophthalmology. Vol 9. 1994:7-24.

2. Aiello LM, Cavallerano JD, Aiello LP, Bursell SE. Diabetic retinopathy. In: Guyer DR, Yannuzzi LA, Chang S, et al, eds. Retina Vitreous Macula. Vol 2. 1999:316-44.

3. Benson WE, Tasman W, Duane TD. Diabetes mellitus and the eye. In: Duane's Clinical Ophthalmology. Vol 3. 1994.

4. Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, ed. Retina. Vol 2. 1994:1243-76.

5. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. Feb 2009;5(1):8-13. [Medline].

6. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. Mar 2009;116(3):497-503. [Medline].

7. Klein R. The Diabetes Control and Complications Trial. In: Kertes C, ed. Clinical Trials in Ophthalmology: A Summary and Practice Guide. 1998:49-70.

8. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev. Feb 2009;5(1):3-7. [Medline].

9. Liew G, Mitchell P, Wong TY. Systemic management of diabetic retinopathy. BMJ. Feb 12 2009;338:b441. [Medline].

10. Akduman L, Olk RJ. The early treatment for diabetic retinopathy study. In: Kertes C, ed. Clinical Trials in Ophthalmology: A Summary and Practice Guide. 1998:15-36.

11. Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina. Jul-Aug 2006;26(6 Suppl):S71-9. [Medline].

12. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. Sep 2008;115(9):1447-9, 1449.e1-10. [Medline].

13. Genuth S. The UKPDS and its global impact. Diabet Med. Aug 2008;25 Suppl 2:57-62. [Medline].

Keywords

background diabetic retinopathy, diabetic retinopathy, BDR, diabetic retinopathy treatment, nonproliferative diabetic retinopathy, NPDR, diabetes mellitus, DM, diabetes mellitus retinopathy, DM retinopathy, blindness, vision loss, visual acuity loss, visual loss, diabetic macular edema, DME

Contributor Information and Disclosures

Author

Abdhish R Bhavsar, MD, Adjunct Assistant Professor, Department of Ophthalmology, University of Minnesota Medical School; Director of Clinical Research, Retina Center, PA; Past Chair, Consulting Staff, Department of Ophthalmology, Phillips Eye Institute
Abdhish R Bhavsar, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Medical Association, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, and Minnesota Medical Association
Disclosure: Allergan Grant/research funds None; genentech Grant/research funds None; regeneron Grant/research funds None; sirion Grant/research funds None

Coauthor(s)

John H Drouilhet, MD, FACS, Clinical Professor, Department of Surgery, Section of Ophthalmology, University of Hawaii, John A Burns School of Medicine
John H Drouilhet, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and American Medical Association
Disclosure: Nothing to disclose.

Medical Editor

V Al Pakalnis, MD, PhD, Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center
V Al Pakalnis, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and South Carolina Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Managing Editor

Steve Charles, MD, Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine; Adjunct Professor of Ophthalmology, Columbia College of Physicians & Surgeons; Clinical Professor Ophthalmology, Chinese University of Hong Kong
Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Club Jules Gonin, Macula Society, and Retina Society
Disclosure: Alcon Laboratories Consulting fee Consulting; OptiMedica Ownership interest Consulting

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Sherman O Valero, MD, to the development and writing of this article.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)